✦ LIBER ✦

High-dose thiotepa and etoposide-based regimens with autologous hematopoietic support for high-risk or recurrent CNS tumors in children and adults

✍ Scribed by Papadopoulos, K P; Garvin, J H; Fetell, M; Vahdat, L T; Garrett, T J; Savage, D G; Balmaceda, C; Bruce, J; Sisti, M; Isaacson, S

Book ID: 110010718
Publisher: Nature Publishing Group
Year: 1998
Tongue: English
Weight: 63 KB
Volume: 22
Category: Article
ISSN: 0007-1188
DOI: 10.1038/sj.bmt.1701408

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

A Phase I Study of High-dose BCNU, Etopo

A Phase I Study of High-dose BCNU, Etoposide and Escalating-dose Thiotepa (BTE) with Hematopoietic Progenitor Cell Support in Adults with Recurrent and High-risk Brain Tumors

✍ Kyriakos P. Papadopoulos; Casilda Balmaceda; Michael Fetell; Elizabeth Kaufman; 📂 Article 📅 1999 🏛 Springer US 🌐 English ⚖ 49 KB

Phase I study of high-dose thiotepa with

Phase I study of high-dose thiotepa with busulfan, etoposide, and autologous stem cell support in children with disseminated solid tumors

✍ Pession, Andrea; Prete, Arcangelo; Locatelli, Franco; Bella, Santiago; Melchiond 📂 Article 📅 1999 🏛 John Wiley and Sons 🌐 English ⚖ 70 KB 👁 2 views

Background. The aim of this phase I study was to define the maximum tolerated dose (MTD) of thiotepa (TT), administered with busulfan (BU) 480 mg/m 2 and etoposide 2,400 mg/m 2 , followed by autologous bone marrow transplantation (ABMT) or peripheral blood stem cell transplantation (APBSCT) support